Habu, Takumi
Kumagai, Shogo
Bando, Hideaki
Fujisawa, Takeshi
Mishima, Saori
Kotani, Daisuke
Nakamura, Masaki
Hojo, Hidehiro
Sakashita, Shingo
Kinoshita, Takahiro
Yano, Tomonori
Mitsunaga, Shuichi
Nishikawa, Hiroyoshi
Koyama, Shohei http://orcid.org/0000-0002-6897-9417
Kojima, Takashi
Funding for this research was provided by:
Japan Agency for Medical Research and Development
Canon Medical Systems Corporation
Mitsubishi Foundation
Takeda Science Foundation
Taiju Life Social Welfare Foundation
Astellas Foundation for Research on Metabolic Disorders
Senri Life Science Foundation
Uehara Memorial Foundation
Chugai Pharmaceutical
Article History
Received: 19 February 2024
Accepted: 23 May 2024
First Online: 31 May 2024
Declarations
:
: H. Bando reports honoraria from Ono Pharmaceutical, Taiho Pharmaceutical and Eli Lilly Japan. D. Kotani reports honoraria from Takeda, Chugai, Lilly, MSD, Ono, Seagen, Guardant Health, Eisai, Taiho, Bristol Myers Squibb, Daiichi-Sankyo, Pfizer, Merckbiopharma, and Sysmex, research funding from Ono, MSD, Novartis, Servier, Janssen, IQVIA, Syneoshealth, CIMIC, and Cimicshiftzero. M. Nakamura reports receiving personal fees from AstraZeneca and a research grant from illumina, outside the submitted work. S. Mitsunaga reports honoraria and research funding from Toray Industries, Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co., Ltd., Astellas Pharma, Ajinomoto, Taiho Pharmaceutical Co., Ltd., PFDeNA outside the submitted work, and personal fees from Ono Pharmaceutical Co. Ltd. outside the submitted work. H. Nishikawa received research funding and honoraria from Ono Pharmaceutical, Bristol-Myers Squibb, Chugai Pharmaceutical, and MSD, honoraria from Amgen and research funding from Taiho Pharmaceutical, Daiichi-Sankyo, Kyowa Kirin, Zenyaku Kogyo, Oncolys BioPharma, Debiopharma, Asahi-Kasei, Sysmex, Fujifilm, SRL, Astellas Pharmaceutical, Sumitomo Dainippon Pharma, and BD Japan outside of this study. S. Koyama has received research funding from Otsuka Pharmaceutical and Chugai Pharmaceuticals. T. Kojima reports receiving research funding from Beigene Ltd., AstraZeneca, Chugai Pharmaceutical, Parexel International, Shionogi, Taiho Pharmaceutical, Astellas Amgen BioPharma, MSD, and Ono Pharmaceutical; honoraria from Ono Pharmaceutical, Covidien Japan, MSD, Boehringer Ingelheim, Kyowa Kirin, EA Pharma, Bristol-Myers Squibb, 3H Clinical Trial, AstraZeneca, Taiho Pharmaceutical, Liang Yi Hui Healthcare Oncology News China, Japanese Society of Pharmaceutical Health Care and Sciences, Oncolys BioPharma, and BMS; advisory roles for Ono Pharmaceutical, Taiho Pharmaceutical, Japanese Society of Pharmaceutical Health Care and Sciences, and Liang Yi Hui Healthcare Oncology News China. All other authors have no conflicts of interest to disclose.
: The study protocol was approved by the Institutional Review Board of the National Cancer Center (2021–2022). This study was conducted in accordance with the Declaration of Helsinki and the Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects.